LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Mineralys Therapeutics, Inc. today and set a price target of $44.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rami Katkhuda’s rating is based on the promising clinical potential of Mineralys Therapeutics, Inc.’s lead candidate, lorundrostat, in treating hypertension. The positive results from pivotal studies, which demonstrated significant reductions in systolic blood pressure with lorundrostat, align with the success seen in similar trials with other aldosterone synthase inhibitors (ASIs), reinforcing confidence in its efficacy.
Furthermore, the upcoming pre-NDA meeting with the FDA and the large market opportunity, given the substantial number of hypertensive patients not achieving adequate blood pressure control, contribute to the optimism surrounding Mineralys. The company’s strategic positioning and the potential for regulatory approval make it a compelling investment opportunity, justifying the Buy rating.